0
Your cart

Your cart is empty

Books > Science & Mathematics > Biology, life sciences > Biochemistry > Proteins

Not currently available

Novartis Foundation Symposium 259 - Reversible Protein Acetylation (Hardcover) Loot Price: R3,824
Discovery Miles 38 240
You Save: R358 (9%)
Novartis Foundation Symposium 259 - Reversible Protein Acetylation (Hardcover): Novartis

Novartis Foundation Symposium 259 - Reversible Protein Acetylation (Hardcover)

Novartis

 (sign in to rate)
List price R4,182 Loot Price R3,824 Discovery Miles 38 240 | Repayment Terms: R358 pm x 12* You Save R358 (9%)

Bookmark and Share

Supplier out of stock. If you add this item to your wish list we will let you know when it becomes available.

The reversible acetylation of lysine residues on histone proteins has emerged as a major factor in the regulation of transcription in eukaryotes. All core histone proteins are acetylated and unique functional chromosomal domains are characterized by specific patterns of acetylation within their histone proteins. Functional correlations have been established between the level of acetylation of individual genes and their transcriptional activity. These complex signals are currently being elucidated in the context of the 'histone code hypothesis'. This model posits that distinct acetylation patterns in histones, along with other post-translational modifications, serve as specific signals recognized by the nuclear transcriptional machinery.

Histone acetylation is under the control of competing histone acetyltransferases (HATs) and histone deacetylases (HDACs). Both enzyme families contain many members: at least 18 distinct human HDACs have been identified. As well as regulating transcription, these proteins play critical roles in cell cycle control and differentiation. Acetylation is not restricted to histone proteins; a growing number of important biological functions appear to be regulated via acetylation. These include DNA binding (p53), nuclear-cytoplasmic shuttling (NF-kB) and coactivator recruitment (HIV Tat protein).

This novel research opens up new and exciting possibilities for drug design. Inhibitors have been developed that specifically target either HDACs or HATs. HDAC inhibitors exhibit selective toxicity towards tumour cells and are being developed as potential anticancer drugs. This book describes current knowledge of acetylation and features extensive discussionsamongst the world's experts in this field, with an emphasis on major unanswered questions.

General

Imprint: John Wiley & Sons
Country of origin: United States
Release date: April 2004
First published: May 2004
Authors: Novartis
Dimensions: 236 x 165 x 19mm (L x W x T)
Format: Hardcover
Pages: 310
ISBN-13: 978-0-470-86261-2
Categories: Books > Medicine > Other branches of medicine > Pharmacology > General
Books > Science & Mathematics > Biology, life sciences > Biochemistry > Proteins
Books > Science & Mathematics > Biology, life sciences > Life sciences: general issues > Genetics (non-medical) > General
LSN: 0-470-86261-0
Barcode: 9780470862612

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners